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Background. Nitric oxide (NO)-signal transduction plays an important role in renal ischemia/reperfusion (I/R) injury. NO
produced by endothelial NO-synthase (eNOS) has protective functions whereas NO from inducible NO-synthase (iNOS) induces
impairment. Rosiglitazone (RGZ), a peroxisome proliferator-activated receptor (PPAR)-γ agonist exerted beneﬁcial eﬀects after
renal I/R injury, so we investigated whether this might be causally linked with NOS imbalance. Methods. RGZ (5mg/kg) was
administered i.p. to SD-rats (f) subjected to bilateral renal ischemia (60min). Following 24h of reperfusion, inulin- and PAH-
clearance as well as PAH-net secretion were determined. Morphological alterations were graded by histopathological scoring.
Plasma NOx-production was measured. eNOS and iNOS expression was analyzed by qPCR. Cleaved caspase 3 (CC3) was
determined as an apoptosis indicator and ED1 as a marker of macrophage inﬁltration in renal tissue. Results. RGZ improves renal
function after renal I/R injury (PAH-/inulin-clearance, PAH-net secretion) and reduces histomorphological injury. Additionally,
RGZ reduces NOx plasma levels, ED-1 positive cell inﬁltration and CC3 expression. iNOS-mRNA is reduced whereas eNOS-
mRNA is increased by RGZ. Conclusion. RGZ has protective properties after severe renal I/R injury. Alterations of the NO pathway
regarding eNOS and iNOS could be an explanation of the underlying mechanism of RGZ protection in renal I/R injury.
1.Introduction
Acutekidneyinjury(AKI)isacommonclinicalcomplication
with uncertain outcome, ranging from complete restitution
to high mortality. Ischemia and reperfusion (I/R) injury
i sam a j o rc a u s eo fA K I ,f r e q u e n t l yo c c u r r i n ga sar e s u l t
of hypotension, hypovolemia, sepsis, or following renal
transplantation [1]. I/R injury causes inﬂammation, renal
epithelial cell death, and a reduced organ perfusion and is
associated with renal dysfunction [2]. The renal inner cortex
and the outer medulla are the predominant morphological
sites of I/R injury [2].
Nitric oxide (NO) is fundamentally involved in the
pathophysiology of ischemic AKI [1, 3]. NO is thought to
exert both protective and deleterious eﬀects depending on
the generating enzyme: the generation of NO by inducible
NO synthase (iNOS) contributes to renal cell injury due to
inﬁltration with inﬂammatory cells, by direct DNA damage
or by apoptotic eﬀects [1, 4, 5]. On the other hand, a reduced
activity of eNOS contributes to renal impairment due to
endothelial dysfunction and consecutive renal vasoconstric-
tion [1, 3].
Our group and others demonstrated that nitric oxide
pathway is altered in ischemic AKI resulting from (i) a
reduced eNOS-expression [6, 7] and (ii) an increased iNOS
expression [4, 8] in renal tissue. A correction of this
eNOS/iNOS imbalance correlates with an amelioration of
renal function after I/R injury [4, 6, 7]. This supports the
hypothesis of the eNOS/iNOS balance playing a prominent
role in the process of renal I/R injury [9].
Rosiglitazone is the most potent activator of the peroxi-
some-proliferator-activated receptor gamma (PPARγ). The
PPARγ belongs to a nuclear hormone receptor superfamily
which regulates transcription by binding to retinoid X2 PPAR Research
receptor that is in turn bound to DNA in various cell types.
Activation of PPARγ promotes insulin-stimulated glucose
uptake and suppresses proinﬂammatory responses [10].
Rosiglitazone protects against renal I/R injury in the
rat [11]. Additionally, PPARγ agonists reduce inﬂammatory
response during renal I/R injury [11, 12]. However, the
underlying mechanisms are not fully investigated yet. Using
inﬂammatory animal models, rosiglitazone signiﬁcantly
reduces the expression of iNOS and the generation of NO
[13–15]. In addition, there is evidence that rosiglitazone may
additionally aﬀect the protective branch of NO production
mediated by eNOS in I/R injury [16]. Consequently, we
hypothesized that rosiglitazone may exert its protective
action in renal I/R damage via inﬂuencing both iNOS and
eNOS.
We tested this hypothesis in our well-established rat
model of I/R injury [4, 5] with rosiglitazone applied during
the ischemic period.
Eﬀects on renal functional outcome were monitored by
glomerular ﬁltration rate (GFR) and renal plasma ﬂow
(RPF). Histomorphological damage was examined and
scored for its severity. The inﬂuence of rosiglitazone on the
imbalanceofeNOSandiNOSexpressionandNOgeneration
wereanalyzed.Cellularinﬂammatoryresponsesvisualizedby
cortical ED-1-positive cell inﬁltration as well as eﬀects on
apoptotic cleaved caspase 3 (CC3) protein expression were
determined.
2.MaterialsandMethods
2.1. In Vivo Experimental Procedure. All animal care and
experimental procedures performed in this study were in
accordance with the German laws for animal protection.
Sprague-Dawley (CD) rats (♀, 200–250g body weight)
were obtained from Charles River Wiga GmbH (Kissleg,
Germany). Anesthesia was performed by intraperitoneal
application of xylacin hydrochloride (10mg/kg body weight)
and ketamine (100mg/kg body weight). All operative pro-
cedures were performed on thermoregulated heating boards
to maintain body temperature at 37.0◦C. Postoperative
pain relief was assured by subcutaneously applied tramadol
(0.05mg/kg body weight); postoperative dehydration was
prevented by subcutaneous administration of an additional
1.0mL of 0.9% NaCl. Animals were divided into the ﬁve
following subgroups:
(i) control group: reﬂecting day 0 (control);
(ii) sham group: supplementation with saline (sham);
(iii) sham group: supplementation with rosiglitazone (sham
+ RGZ);
(iv) clamping group: supplementation with saline (clamp);
(v) clamping group: supplementation with rosiglitazone
(clamp + RGZ).
I/R injury was induced in rats by bilateral clamping of
the renal arteries for 45 and 60 minutes as described pre-
viously [4, 5] .T h es a m ep r o c e d u r ew a sp e r f o r m e di ns h a m
animalswithoutthebilateralclampingprocess.Rosiglitazone
(5mg/kg ip) or saline, respectively, were given intraperi-
toneally before the end of the clamping period (or after
sham operation) to assure immediate delivery into the
kidney right at the beginning of reperfusion and to exclude
preconditioningpretreatmenteﬀectsofrosiglitazonepriorto
ischemia. Control animals remained completely untreated.
2.2. Measurement of Clearances of Inulin (GFR) and PAH
(RPF). Inulin and PAH clearances were calculated by using
inulin (ﬂuorescein-isothiocyanate inulin) or paraaminohi-
purate (both from Sigma Aldrich, St. Louis, MO, USA)
concentrations in plasma and urine samples as recently
described in detail [5].
2.3. Organ Preparation and Tissue Harvesting. After per-
fusion under pressure-controlled conditions (100mmHg)
with ice-cold Krebs buﬀer [in mM: 118NaCl, 25NaHCO3,
4.8KCl, 1.2KH2PO4,1 . 2 M g S O 4,1 1g l u c o s e ,a n d1 . 5
CaCl2(2H2O)] for 20s, samples of renal cortex including
parts of the outer medulla were removed from whole kidney,
snap-frozen in liquid nitrogen, and stored at −80◦C.
2.4. Protein Immunoblotting. For western blot analysis, fro-
zen kidney cortices were mechanically homogenized and
dissolvedinlysisbuﬀercontaining150mMNaCl,10mmol/L
Tris (Base) pH 7.3, 1% Nonidet P40 (Igepal), 0.1% SDS,
1% sodium-desoxychloric acid, 0.1% Triton X-100, 1mM
EDTA, 184mg/L sodium orthovanadate, and 0.1% protease
inhibitor cocktail (100mM AEBSF-HCl, 80mM aprotinin
(bovine lung, crystalline), 5mMbestatin, 1.5mM protease
inhibitor E-64, 2mM leupeptin hemisulfate, and 1mM
papstatin A). Total protein was measured in each sample
using the Bradford method.
Samples of protein (30μg) were analyzed by Western
blot with the cleaved caspase 3 polyclonal antibody (diluted
1:250, Cell Signaling, Boston, MA, USA). Blots were incu-
bated with horseradish peroxidase-conjugated anti-rabbit
IgG (1:2,000; Dako, Hamburg, Germany) and developed
using a chemiluminescence kit (ECL Plus, Amersham, GE
Healthcare, Buckinghamshire, UK) following the manufac-
turer’s instruction. Each gel was speciﬁcally corrected for
loadingcontrolusingβ-actin(diluted1:50.000)asreference.
All western blots were analyzed densitometrically by using
the ImageJ software (http://rsbweb.nih.gov/ij/) and plotted
with SigmaStat/SigmaPlot software (Systat Software, San
Jose, CA, USA).
2.5. Real-Time RT-PCR. RNA from kidney cortices were ex-
tracted using the Qiagen RNA Isolation Kit (Qiagen, Hilden,
Germany). RNA concentration was determined, and cDNA
was synthesized using the iScript cDNA synthesis kit (Bio-
Rad Laboratories Inc, Benicia, CA, USA) according to the
manufacturer’s instructions. In brief, RT-PCR was per-
formed according to the iQ SYBR-Green Supermix RT-PCR
system protocol (Bio-Rad Laboratories Inc, Benicia, CA,
USA). Initial denaturation was performed at 95◦C for 3min.
PCR ampliﬁcation was performed as described in respective
references. iNOS and eNOS were determined as described byPPAR Research 3
Ca˜ nueloetal.[17].ForiNOS,theprimerswere5 -GCAGGT
TGA GGA TTA CTT CTT CCA-3  (sense) and 5 -GCC CTT
TTT TGC TCC ATA GGA AA-3  (antisense), resulting in an
94-bp RT-PCR product. For eNOS, the primers were 5 -CAC
ACT GCT AGA GGT GCT GGA A-3  (sense) and 5 -TGC
TGA GCT GAC AGA GTA GTA C-3  (antisense), resulting
in a 109-bp RT-PCR product. For β-actin, the primers were
5 -TCT ACA ATG AGC TGC GTG TG-3  (sense) and 5 -
TAC ATG GCT GGG GTG TTG AA-3  (antisense), resulting
in an 129-bp RT-PCR product. The RT-PCR products
generated with primers for iNOS and eNOS were tested
by sequencing (MWG Biotech, M¨ unchen, Germany) and
were found to represent the predicted parts of the respective
m R N A s .T h eR T - P C Rp r o d u c t sw e r et e s t e df o rc o r r e c ts i z e
by agarose gel electrophoresis and melting point analysis.
Quantiﬁcation was performed using the ΔΔCT method with
β-actinasareferencegene.Expressionincontrolanimalswas
normalized to 100.
2.6. Detection of Nitric Oxide. Nitrate and nitrite (NOx)
in the plasma level was determined to measure the NO
generation. Detection of NOx was performed using the
nitrate/nitrite colorimetric assay kit obtained from Cayman
Chemical Company (Ann Arbor, MI, USA) in a 96-well plate
according to the manufacturer’s protocol.
2.7. Detection of Invading Monocytes/Macrophages. Immun-
oﬂuorescence detection of invading ED-1-positive cells was
done as previously described in detail [18]. In brief, cryo-
stat sections (5μm) were ﬁxed in PBS buﬀer with 4%
paraformaldehyde at a temperature of 4◦C for 10min. After
being rinsed with PBS, buﬀer sections were blocked with
50mM NH4Cl for another 10min, followed by another
rinsing in PBS. Additionally, sections were incubated with
0.1% Triton X-100 in PBS buﬀer for 10min. Finally, they
were blocked with 10% donkey serum in 0.1% Triton X-100
in PBS buﬀer for 1h. Subsequently, the anti-rat macrophage
ED-1 (CD68) antibody (diluted 1:400; Acris BM 4000,
Herford, Germany) was incubated in 10% donkey serum in
PBS buﬀer, followed by donkey anti-mouse Cy3-conjugated
secondary antibody (diluted 1:500; model 715-165-151;
Dianova, Hamburg, Germany) in 10% donkey serum for
1h. After a last rinse in PBS and H2O, ED-1 visualisation in
renal tissue sections was performed using an epiﬂuorescence
microscope (NIKON Eclipse TE 2000-S, Tokyo, Japan).
Finally, the quantity of ED-1 positive cells was determined
by calculation of the mean value from the manually counted
number in three randomly deﬁned visual ﬁelds of each renal
section.
2.8.HistopathologyandScoringfortheSeverityofInjury. Cry-
ostat sections (5μm) were ﬁxed in acetone (Baker, Holland).
Sections were stained with periodic acid-Schiﬀ (Roth, Ger-
many)(PAS)andcounterstainedwithHematoxylinSolution,
Gill No. 3 (GHS 332-1l). Histopathologic alterations of the
kidney (interstitial edema, ablation of tubular epithelium
from the basement membrane, ablation of the brush border
from the epithelium of the proximal tubuli, and cell death)
were analyzed semiquantitatively by a blinded investigator
according to a score (0–3) which was described previously in
detail [19]. Mean values from the separate scores were taken
together as total injury score.
2.9. Data Analysis and Materials. Data are presented as
means ± SEM. The n values are given in the text or in the
ﬁgures. n equals the number of rats or experiments (RT-
PCR, western blot) with tissue or tissue extractions from
distinctive rats.
Statistical signiﬁcance was determined by unpaired Stu-
dent’s t-test for all experiments except for the measure-
ment of NOx and the histopathologic scores. For NOx-
levels statistical signiﬁcance was determined by ANOVA test
followedbypairwisemultiplecomparisonusingtheStudent-
Newman-Keuls-Test. For histopathologic scores diﬀerences
were assessed using Kruskal-Wallis-Test performed with
SPSS 19.0 statistical software (Systat Software, San Jose, CA,
USA). Diﬀerences were considered statistically signiﬁcant
when P<0.05.
Rosiglitazone (RGZ, AVANDIA) was purchased from
GlaxoSmithKline (Brentford, Middlesex, UK). Tramadol
( T r a m a l)w a sf r o mG r¨ unenthal GmbH (Aachen, Germany),
xylacin hydrochloride (Rompun ) was from Bayer AG
(Leverkusen, Germany), and ketamine (Ketanest ) was from
Pharmacia & Upjohn Inc (Bridgewater, NJ, USA). If not
indicatedotherwise,allsubstancesweredilutedin0.9%NaCl
(w/v). If not stated otherwise, chemicals were from Sigma
Aldrich (St. Louis, MO, USA).
3. Results
3.1. Rosiglitazone Improves Parameters of Renal Function in
Severe Renal I/R Injury. Comparison of control animals
(reﬂecting day 0) with sham-treated animals revealed no
diﬀerence of both GFR and RPF (measured by inulin and
PAH clearance) (Figures 1(a),a n d1(b)). This indicates
that the surgical procedure itself had no eﬀect on renal
function. Moreover these results show the reliability of the
applied method by being in good accordance with the results
published by our group before [4, 5]. In sham-operated rats,
rosiglitazone application neither aﬀected inulin clearance
nor PAH clearance 24h after intervention. As expected,
severe I/R injury with a 60min ischemic time caused a
signiﬁcant decline in inulin clearance reﬂecting a marked
glomerular dysfunction (Figure 1(a)). Rosiglitazone attenu-
ated the decrease of inulin clearance. Nevertheless, inulin
clearance was still substantially lower compared to sham-
treated animals or control.
A similar proﬁle was observed for PAH clearance.
Rosiglitazone application provided a threefold improvement
of PAH clearance in severe I/R injury when compared
to untreated postischemic animals (Figure 1(b)). However,
PAH clearance was still substantially diminished despite
rosiglitazone treatment in severe I/R injury in comparison
to sham-treated animals or controls.
In summary, the distinct decrease of inulin and PAH
clearance in severe renal I/R damage was moderately but
signiﬁcantly attenuated by rosiglitazone.4 PPAR Research
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Figure 1: Eﬀect of 5mg/kg rosiglitazone (RGZ) on parameters of renal function in Sprague-Dawley rats in renal I/R injury. After either a
sham operation or a bilateral clamping of the renal arteries for 60min, rosiglitazone was applied i.p. or not, and parameters of renal function
were determined 24h afterwards. Parameters were additionally determined in untreated control rats. n as indicated. #Statistically signiﬁcant
diﬀerence asindicated. (a) Renal clearance of inulinwas determined as ameasureof GFRas described in Section 2(GFR = (IU ×VU)/(IP×t),
where IU is inulin concentration in urine, IP is inulin concentration in plasma, VU is urine volume, t is time of measurement, and GFR is
glomerular ﬁltration rate). (b) Renal clearance of PAH was determined as described in Section 2 (PAH clearance = (PAHU ×VU)/(PAHP ×t),
where PAHU is PAH concentration in urine, PAHP is PAH concentration in plasma). (c) Renal net secretion of PAH (PNS) was determined
as described in Section 2 {PNS = [(PAHU ×VU)/t] −[GFR × PAHP]}.
3.2. Rosiglitazone FailstoImprove RenalFunctionSigniﬁcantly
in Moderate I/R Injury. In an in vivo model of renal I/R
injury caused by an ischemic period of 45min, treatment
with rosiglitazone showed a trend towards improvement
of renal functional parameters (GFR, RPF) but failed to
reach statistical signiﬁcance (data not shown). Possibly
the expected protective eﬀects were not strong enough to
induce a signiﬁcant functional amelioration as discussed
later. Increasing the dose of rosiglitazone was in our opinion
no favorable option with respect to the overall daily dose
recommended for humans (8mg/d).
Therefore, we further analyzed the data obtained from
our model of severe ischemic AKI with extended ischemic
period of 60min.
3.3. Rosiglitazone Improves PAH Net Secretion (PNS) in
Renal I/R Injury. Since PAH clearance is dependent on both
renal perfusion and net secretion of PAH via proximal
tubularcells,PAH-net secretion (PAH-NS)wassubsequently
investigated to clarify the mechanism for the increase of PAH
clearance. Likewise, reduction of PAH-NS was attenuated in
part by rosiglitazone in renal I/R damage (Figure 1(c)). This
indicates an improvement proximal tubular cell function
mediated by rosiglitazone. In sham-treated animals neither
rosiglitazone nor vehicle signiﬁcantly inﬂuenced PAH-NS.
Rosiglitazone induced a more intense increase of PAH
clearance (+330%) compared to PAH-NS (+210%) follow-
ing severe I/R injury. This indicates that the rise of PAH
clearance is not exclusively based on an increase of PAH-NSPPAR Research 5
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Figure 2: Eﬀect of rosiglitazone (RGZ) on morphological alterations in the kidney of Sprague-Dawley rats in renal I/R injury. Renal
cryostat sections were stained with periodic acid-Schiﬀ (PAS). Injury was graded by a score as described in Section 2. (a) Total injury score
(mean values from Figure 2(b) were taken together). n as indicated. #, ∗ statistically signiﬁcant diﬀerence as indicated. (b) Single criteria of
histopathologic investigations are shown. n from 4 to 6 for each group. ∗Statistically signiﬁcant diﬀerence (P<0.05) between clamp versus
clamp + RGZ; $statistically signiﬁcant diﬀerence (P<0.05) between control, sham, sham + RGZ versus clamp and clamp+RGZ; statistically
signiﬁcant diﬀerence (P<0.05) between control, sham, sham + RGZ versus clamp alone. (c) Representative sections of images of the renal
cortex after PAS staining are shown. Control group, clamp group, and clamp + RGZ group as indicated on the sections. Some of the lesion
criteria are exempliﬁed. Arrowhead points to loss of the brush border. Arrow shows vacuolization in epithelial cells of the tubuli. Lines
without arrowheads show tubular epithelial cells with defragmented nuclei.
(and therefore on proximal tubular cell function) but is also
due to improvement of renal perfusion as well.
3.4. Rosiglitazone Reduces Histomorphological Damage in Se-
vere Renal I/R Injury. Histopathologic observations revealed
that total injury score was signiﬁcantly increased in both
clamping groups compared to the other groups. Treatment
with rosiglitazone in the severe I/R injury model resulted
in a signiﬁcant reduction of histomorphological damage.
Formation of cell edema and vacuolization were signiﬁcantly
increased only in the clamping group without rosiglitazone.
Increased interstitial edema, loss of brush border in the
proximal tubular cells, cell death, and detachment of base-
ment membrane were visible in both clamping groups, but
signiﬁcantly reduced in rosiglitazone treated clamping group
compared to untreated clamping group (Figures 2(a)–2(c)).
3.5. eNOS mRNA Is Upregulated by Rosiglitazone in Renal I/R
Injury. It is well known that eNOS plays an important role
in the regulation of renal perfusion [1, 3]. Additionally, it is6 PPAR Research
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Figure 3: Eﬀect of 5mg/kg rosiglitazone (RGZ) on the mRNA levels of (a) endothelial and (b) inducible NO-Synthase (eNOS and iNOS)
in Sprague-Dawley rats in renal I/R injury. Total RNA was generated from kidney cortex. Real-time PCR against eNOS, iNOS, and β-actin
was performed as described in Section 2. Quantiﬁcation was performed using the DDCT method using β-actin as a reference gene, and
expression in untreated control animal (control 0h) was normalized to 100. n is given in the respective bars. (a) Eﬀect RGZ on the mRNA
levels of eNOS. The amount of eNOS mRNA signal normalized to the respective signal from β-actin. #,∗ Statistically signiﬁcant diﬀerence as
indicated. n.s.: Statistically not signiﬁcant. (b) Eﬀect of RGZ on the mRNA levels of iNOS. The amount of iNOS mRNA signal normalized
to the respective signal from β-actin. #,∗ Statistically signiﬁcant.
known that PPARγ agonists can induce renal eNOS expres-
sion in rats [20]. In vehicle-treated animals, I/R damage
led to a signiﬁcant reduction of eNOS mRNA expression
in renal cortex when compared to controls or sham-treated
animals 24h after intervention. Compared to vehicle, eNOS
RNA expression was less diminished with rosiglitazone
application in severe I/R injury. There was no signiﬁcant
diﬀerence between rosiglitazone-treated clamp animals and
sham animals or controls. (Figure 3(a)).
3.6. iNOS mRNA Is Downregulated by Rosiglitazone in Renal
I/R Injury. iNOS is known to play an important role in
the pathophysiology of renal I/R injury [3]. Chen et al.
showed that iNOS-mRNA is substantially upregulated in
renal I/R injury [8]. In our study, iNOS mRNA cortical
expression considerably increased (400%) in renal I/R injury
period when compared to sham-treated animals or control.
Rosiglitazone almost totally abrogated this distinct iNOS
increase (Figure 3(b)), resulting in iNOS mRNA expression
similartosham-treatedanimalsorcontrol.Rosiglitazonehad
no signiﬁcant eﬀect on iNOS mRNA expression of sham-
treated animals.
3.7. Rosiglitazone Diminishes NOx Production in Renal I/R
Injury. Schwartz et al. demonstrated that iNOS mediates
regulationofeNOSviatheNOSproductNO[21].Therefore,
concentration of both nitrite and nitrate as an established
marker of NO generation was determined. Severe renal
I/R injury resulted in a signiﬁcant increase of plasma
NOx when compared to sham-operated animals (Figure 4).
Rosiglitazone decreased the elevated NOx levels in severe
I/R injury. There was no increase of NOx in sham-treated
0
20
40
60
80
100
#
7 9 8 88
#
P
l
a
s
m
a
 
N
O
x
(
μ
M
)
Sham 
+ RGZ
Clamp 
+ RGZ
Control Sham Clamp
∗
Figure 4: Eﬀect of 5mg/kg rosiglitazone (RGZ) on nitrite/nitrate
(NOx) concentration in plasma of Sprague-Dawley rats in renal I/R
injury. NOx as a measure of NO was detected by Griess-reaction as
described in Section 2.N O x concentration is given in μM. n is given
in the respective bars. ∗, # Indicate statistically signiﬁcant diﬀerence
with P<0.05.
animals.Noteworthy,theNOx-levelscorrelatewiththeiNOS
mRNA expression, indicating that iNOS is the major source
of NOx in severe I/R injury.
3.8.CleavedCaspase3ExpressionIsDownregulatedbyRosigli-
tazone in Severe Renal I/R Injury. The protein expression of
CC3 is a marker of cell apoptosis [18]. The expression ofPPAR Research 7
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Figure 5: Eﬀect of 5mg/kg rosiglitazone (RGZ) on the relative
expression of cleaved caspase 3 (CC3) in renal cortex of Sprague-
Dawley rats in renal I/R injury. Antibody against CC3 recognized a
band in the range of 18kDa; the anti-β-actin antibody recognized a
band at 42kDa. The amount of CC3 Western blot against CC3 and
β-actinwasperformedasdescribedinSection 2.Westernblotsignal
was normalized to the respective signal from β-actin. ∗Statistically
signiﬁcant diﬀerence with P<0.05; n as indicated.
cleavedcaspase3(CC3)isincreasedinsevereI/Rinjurywhen
compared to sham-treated animals or control (Figure 5).
This is in good accordance with results from Raﬀ et al.
[18]. This increase of CC3 in severe I/R injury was totally
abrogated by the application of rosiglitazone (Figure 5).
Notably, rosiglitazone led to an opposite CC3 regulation
withasigniﬁcantincreaseofCC3expressioninsham-treated
animals.
3.9. Invasion of ED-1 Positive Cells Is Reduced by Rosiglitazone
in Severe Renal I/R Injury. It is well known that mono-
cytes/macrophages invade the renal cortical tissue in I/R
injury as a part of a postischemic inﬂammatory response.
The detection of ED-1-positive cells reﬂecting invading
monocytes/macrophages in renal I/R injury is well described
[18]. The amount of renal cortical ED-1-positive cells was
determined as an estimate of renal inﬂammatory response
in severe I/R injury. Here, I/R injury signiﬁcantly increased
the amount of ED-1-positive cells, whereas rosiglitazone
averted the cell inﬁltration indicating a reduction of renal
inﬂammatory response (Figure 6). In sham-treated animals
both CC3 expression (as already mentioned above) and ED-
1 inﬁltration were slightly but signiﬁcantly increased when
rosiglitazone was applied. At the moment we can only spec-
ulate about proapoptotic and inﬂammatory responses due to
rosiglitazone. However, since there is no diﬀerence in renal
function among the sham-treated group versus controls
24hafterintervention,theseproapoptoticandinﬂammatory
eﬀects of rosiglitazone seem not to be functionally relevant.
4. Discussion
Inthepresentstudy,theeﬀectofthePPARγ agonistrosiglita-
zonewasinvestigatedinawell-establishedmodelofischemic
acute kidney injury [4–6, 18]. The application of rosigli-
tazone tended to result in an improvement of renal func-
tional parameters regarding an ischemia period of 45min.
However—in contrast to other studies [11, 12]—this trend
was not signiﬁcant. In the related studies [11, 12] the
protocol included repeated applications of rosiglitazone and
a shorter period of reperfusion (6h) in comparison to this
study (24h). Moreover, both studies [11, 12] used male rats.
In renal I/R injury there is a sexual dimorphism with female
rats being much more resistant to ischemia most probably
due to their hormonal status [22].
Consequently we speculate that the protective eﬀect of
rosiglitazone may depend on the extent of renal damage.
In our study, the use of more resistant female rats may
have blurred the eﬀect of rosiglitazone in renal I/R injury
with an ischemic period of 45min. Increasing the dose
might have rendered the protective eﬀect of rosiglitazone
signiﬁcant in our model of renal I/R injury with an ischemia
period of 45min. However, as already mentioned, the body
weight adapted dose was already in the upper range of
recommended dose in human. This is especially impor-
tant as impaired renal function implies the risk of drug
accumulation as renal tubular excretion of rosiglitazone is
mediated by organic cation transporter 1 which depends on
renal function [23]. Thus, we did not increase the dose of
rosiglitazone but enlarged renal damage by extending the
ischemic period.
As far as we know, we are the ﬁrst to investigate the
eﬀect of rosiglitazone in a model of severe kidney injury
deﬁned by an ischemia period of 60min and a reperfusion
period of 24h. The administration of rosiglitazone in severe
renal I/R injury almost tripled GFR (as determined by
inulin-clearance). However, in comparison to sham-treated
animals, renal function was still markedly reduced despite
rosiglitazone treatment.
Besides GFR, rosiglitazone improved PAH clearance
(reﬂecting RPF) in severe renal I/R injury. Since PAH net
secretion itself is ameliorated by rosiglitazone, it is hardly
possible to determine to what extent rosiglitazone improves
renalperfusionfromourdata.However,inpostischemicani-
mals treated with rosiglitazone the PAH clearance increased
to a higher extend (∼350% compared to vehicle) as com-
pared to PAH net secretion (∼200% compared to vehicle).
This is indicative for improved vascular function due to
rosiglitazone. For the ﬁrst time, it is demonstrated that a
PPARγ agonist improved PAH net secretion. PAH is secreted
by the organic anion transport system located in the renal
proximal tubular cells. Since the expression of the rate-
limiting transporters for PAH secretion (OAT 1 and 3) is not
changed by rosiglitazone (data not shown) it seems obvious
that the amelioration of PAH net secretion is due to reduced
tubular damage and improved tubular integrity.
Correspondingtotheameliorationoffunctionalmarkers
we observed reduced histomorphological damage in severe8 PPAR Research
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Figure 6: Eﬀect of 5mg/kg rosiglitazone (RGZ) on invasion of ED-1-positive cells (monocytes/macrophages) in renal cortex of Sprague-
Dawley rats in renal I/R injury. (a) ED-1-positive cells were detected in renal cryostat sections by immunoﬂuorescence as described in
Section 2. (a) Macrophage/monocyte invasion is given as the amount of ED-1-positive cells per visual ﬁeld. n as indicated. ∗ and # indicate
statistically signiﬁcant diﬀerence with P<0.05. (b) Representative immunohistochemistry images of the renal cortex (magniﬁcation 1:10)
after ED1 staining are depicted. Respective groups as indicated on the sections.
I/R injury when rosiglitazone was applied. This is in good
accordance with previous studies [11, 12].
InrenalI/Rinjurycellulardamageismediatedbyinﬂam-
mation and cell apoptosis [1, 2]. Indeed, analyzing inner
renal cortex and outer medulla, the expression of cleaved
caspase 3 which is an established marker of apoptosis
[18] was elevated. Moreover the number of ED-1-positive
inﬂammatory cells was increased in our model of severe I/R
injury. The application of rosiglitazone inhibited the rate
of apoptosis and attenuated renal inﬂammation. Likewise,
previous studies demonstrated similar results investigating
the eﬀect of rosiglitazone on renal ischemia [11]o ro n
cisplatin-induced nephrotoxicity in mice [24].
In acute kidney injury iNOS is fundamentally involved in
theprocessofkidneydamagebyinﬂammationandapoptosis
(Figure 7). The inhibition of iNOS activity (or the absence
of iNOS itself in KO-mice) ameliorates renal I/R damage in
vivo [25, 26]. In the present study, we report that severe I/R
injury causes a strong increase of iNOS mRNA expression
subsequently followed by the increased production of NO.PPAR Research 9
This is in good accordance with previous studies [4, 8, 12,
27].WeshowthatinsevererenalI/Rinjurytheapplicationof
rosiglitazone not only inhibited generation of apoptosis and
attenuated inﬂammation but also abolished the induction of
iNOS and the production of NO. This is in good accordance
with in vitro studies reporting that attenuation of iNOS
expression is associated with a reduction of parameters of
inﬂammation and apoptosis as well as reduced proximal
tubular cell damage [28, 29]. Chatterjee et al. report that
the PPARγ agonist 15-deoxy-Δ12,14-prostaglandin J2 reduces
iNOS induction and NO production in rat proximal tubular
cells [12]. iNOS is expressed in renal tubular cells and in
invading inﬂammatory cells like macrophages [1, 2, 14,
29]. From our data, it is not possible to discriminate the
origin of iNOS expression. However, Schrier et al. and many
studies [1, 4, 8, 13, 15] indicate that the deleterious eﬀect of
increased iNOS expression in tissue is mainly independent
from its origin. In the present study an attenuated increase of
iNOSexpressioncanbedemonstratedevenwheninﬁltration
of inﬂammatory cells is almost completely inhibited by
rosiglitazone. Assumedly, the induction of iNOS is mediated
by both the inﬁltration of inﬂammatory cells and an
upregulationintubularcellsitself.Insummary,rosiglitazone
seems to reduce tubular dysfunction and improve renal
outcome by aﬀecting iNOS expression and its inﬂammatory
and apoptotic responses in this model of severe I/R injury.
The regulation of eNOS and its product NO plays a
major role in renal perfusion and glomerular function in
physiological and pathophysiological conditions [3, 9]. In
the present study, the expression of eNOS is reduced in
I/R injury [6, 7]. The overexpression of iNOS and the
inﬂammatory response may result in a reduced expression
of eNOS [21, 30]. Consequently, the iNOS upregulation
most likely contributes to eNOS reduction in the present
modelaswell.Theadministrationofrosiglitazoneattenuated
the downregulation of eNOS mRNA expression which was
accompanied by an amelioration of GFR and RPF. A correla-
tion of eNOS expression to renal function following kidney
damage was reported by previous studies [6, 7]. Concerning
the eﬀect of PPARγ agonists on eNOS expression in the
literature, Song et al. demonstrate an increase of renal eNOS
expression by treatment with rosiglitazone [20]. However,
other studies suggest that there is no inﬂuence of PPARγ
agonists on eNOS expression [31, 32]. The conﬂicting data
may result either from the use of PPARγ agonists less potent
than rosiglitazone or from the analysis of diﬀerent target
organs (heart, vascular system). In summary, we are the ﬁrst
to investigate the positive inﬂuence of a PPARγ agonist on
eNOS expression which is most probably associated with an
improvement of renal vascular function in renal I/R injury.
We show that the renal expression levels of eNOS and
iNOS are contrariwise altered in severe renal I/R injury.
This is in good accordance with the literature, signiﬁcantly
attenuated eNOS activity (87% decrease) and augmented
iNOS activity (80% increase) in renal cortex of rats subjected
to I/R injury was described previously [33]. As already
mentioned in Section 1, iNOS and eNOS have diﬀerent
eﬀects in renal I/R injury. Increased expression of iNOS
plays a key role in cytotoxicity by inﬂammation response,
necrosis, and apoptosis (Figure 7). Moreover, increased
iNOSexpressionisdescribedtoreduceeNOSexpression[21,
30].ReducedeNOSexpressionimpairsvascularfunctionand
renal perfusion. In the present study, it has been demon-
strated for the ﬁrst time that rosiglitazone exerts its bene-
ﬁcial eﬀects on renal function by both lowering increased
iNOS expression and raising reduced eNOS expression
(Figure 7).
Both eNOS and iNOS produce NO. In the present study,
the serum level of nitrite and nitrate as markers of NO
level are increased after ischemic acute kidney injury (iAKI)
while the application of rosiglitazone signiﬁcantly reduced—
but not normalized—the levels. From our data, it is not
possible to discriminate between eNOS-derived and iNOS-
derived NO production. However, NO production of active
inducible NOS is known to far exceed the NO production
of eNOS [34]. In addition, NO production by eNOS is
reduced in iAKI [1, 3, 6, 9]. Therefore, the rise of NO plasma
l e v e li sm o s tl i k e l ya t t r i b u t e dt oi N O Sg e n e r a t i o ni nI / R
injury. This assumption is in good accordance with data
from other studies [12, 27]. Moreover, a reduced expression
of iNOS mRNA correlates with reduced NO serum levels
[12]. In the present study, the decrease of NO plasma
level mediated by rosiglitazone (about 30%) contrasted the
marked downregulation of iNOS (about 60%). One possible
explanation may be that NO was measured indirectly by
its metabolites, which are in part excreted by the kidneys.
As deteriorated renal function is only in part restored by
rosiglitazone, NO metabolites may accumulate even if iNOS
expression is already markedly reduced.
In addition to altering the transcriptional status, PPARγ
agonists can stimulate endothelial NO release by modulat-
ing posttranslational mechanisms of eNOS regulation. In
vitro, rosiglitazone increases heat shock protein 90-eNOS
interaction [35] and induces a phosphorylation of eNOS
at Ser-1177 [36]. Both mechanisms result in a signiﬁcantly
increasedproductionofNO.Inourinvivostudyitispossible
that posttranslational modiﬁcations augmented the eNOS
activity as well and contributed to an increased NO release.
Besides the inﬂuence on the transcriptional pathway by
activatingperoxisomeproliferator-activatedreceptor,rosigli-
tazone is known to exert protective eﬀects independent from
PPAR. In ischemic stroke rosiglitazone is antiinﬂammatory
by directly reducing NfκB activity and has antiapoptotic
properties by preserving intracellular ATP levels [37].
Although high doses of rosiglitazone are necessary to elicit
PPAR-independent responses [38] we cannot exclude that
rosiglitazone has antiapoptotic and antiinﬂammatory eﬀects
in renal ischemia/reperfusion injury which are independent
from PPARγ. Consequently, these eﬀects of rosiglitazone
may additionally contribute to renal functional and mor-
phological amelioration in I/R injury. An object for further
studies will be the question whether the additional use of a
speciﬁc PPARγ antagonist like GW9662 can block the eﬀects
of rosiglitazone in renal I/R injury.
At the moment from the data given we have no expla-
nation in detail why protection might be more pronounced
after severe ischemia with extended clamping time. We can
only speculate about this fact. One possible explanation10 PPAR Research
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Figure 7: Schematic ﬁgure of factors contributing to renal dysfunction in ischemia/reperfusion injury. The downregulation of eNOS causes
endothelialdysfunctionandvasoconstriction.TheupregulationofiNOSinacutekidneyinjuryisassociatedwithanincreaseincellapoptosis
and inﬂammatory cell damage. Moreover, elevated levels of iNOS directly suppress the expression of eNOS. The application of rosiglitazone
in ischemic acute kidney injury and reperfusion may help to correct the imbalance of eNOS/iNOS expression.
could be that the extent of eNOS/iNOS imbalance seems to
depend on duration of ischemic period. Chen et al. demon-
strated that eNOS mRNA is not down, but upregulated after
45min of ischemia and 24h of reperfusion [8], whereas
we showed a signiﬁcant eNOS downregulation with 60min
ischemic period.
Beside eNOS/iNOS imbalance, other mediators are de-
scribed to contribute to renal damage and dysfunction in
I/R injury, for example, accumulation of free Ca2+ in cytosol
and calpain, releasing of TNF-alpha and other cytokines or
generation of oxygen radicals and generation of tubular casts
[1].
These other multiple pathways involved in renal I/R in-
jury and not aﬀected by rosiglitazone may explain the con-
trast between the distinct improvement of altered inﬂamma-
tory and apoptotic markers corresponding with the reduc-
tion of renal histomorphological damage and the rather
moderate improvement of renal function by rosiglitazone.
One should take into consideration that a reperfusion
period of 24 hours after a severe renal injury with 60min
of ischemia is a short time for restoring the plenitude of
the complex renal functions. Previous studies of our group
showthatcompleterecoveryofrenalfunctionafterI/Rinjury
with a clamping time of 45 minutes takes several days [4].
Based on that we speculate that an even more pronounced
functional recovery due to rosiglitazone might take place
when our ﬁndings of apoptotic and inﬂammatory inﬁltrative
m a r k e r sa sw e l la sh i s t o l o g i cp a r a m e t e r sa r ee x t r a p o l a t e do n
a prolonged subsequent follow-up time. This explanation
could bridge the gap between the strong antiinﬂammatory,
antiapoptotic properties, and the histopathologic improve-
ment on the one hand and the moderate increase of renal
function on the other hand. The eﬀect of rosiglitazone on
long-term functional renal recovery after severe I/R injury is
therefore an interesting task for future studies.
5. Conclusion
We are the ﬁrst to show that (i) rosiglitazone (5mg/kg)
applied in a single dose has functional and histomorpho-
logical beneﬁcial eﬀects in a model of severe ischemia
(60min)/reperfusion injury after a 24h period of reperfu-
sion. (ii) This improvement of renal outcome is linked to a
reduction of increased inﬂammatory and apoptotic markers
as well as a reversed eNOS mRNA downregulation and iNOS
mRNA upregulation. We hypothesize that rosiglitazone
improves renal outcome in I/R injury by rebalancing these
key enzymes of the nitric oxide pathway (Figure 7).
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